Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD – The Liver Meeting® 2024
WARMINSTER, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”) a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with...